24/7 Market News Snapshot 01 July, 2025 – Cybin Inc. (NYSE:CYBN)

July 1, 2025

DENVER, Colo., 01 July, 2025 (www.247marketnews.com) – (NYSE:CYBN) are discussed in this article.
Cybin Inc. has recently made notable strides in its business and clinical initiatives, coinciding with a significant market response as its shares demonstrated an impressive increase. The company, recognized as a trailblazer in neuropsychiatry and dedicated to innovating mental health treatments, opened trading today at $8.92 and rose to approximately $9.145, reflecting a strong upward momentum of around 9%. This increase follows a previous closing price of $8.39, signaling positive investor sentiment. The trading volume reached 644.07K, showcasing active engagement that may contribute to enhanced price stability.

Cybin’s positive performance follows the release of its financial results for the fiscal year ending March 31, 2025, which highlights its strategic advancements and progress toward key clinical and regulatory milestones. CEO Doug Drysdale expressed optimism regarding the company’s direction, particularly in view of supportive comments from Food and Drug Administration officials on innovative mental health treatments. Cybin is diligently advancing its clinical candidates: CYB003, a Phase 3 program aimed at major depressive disorder, and CYB004, currently in Phase 2 for generalized anxiety disorder.

The company’s strategic collaborations with partners, including Osmind and Thermo Fisher Scientific, are expected to bolster its development and commercialization processes. Promising outcomes from clinical trials have emerged, particularly a remarkable 100% response rate in the Phase 2 study for CYB003. The ongoing Phase 2 study for CYB004 is projected for completion around mid-2025, further exemplifying Cybin’s commitment to transforming mental health care.

With a robust portfolio of over 90 granted patents and C$135 million in cash reserves, Cybin is well-positioned to lead advancements in the rapidly evolving neuropsychiatry landscape, underscoring its dedication to delivering next-generation therapeutic solutions.

Related news for (CYBN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.